High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State
CVS Health Corp (CVS) delivered a 40% surge in adjusted EPS, raised its full-year outlook, and outlined a clear path to offset 2027 headwinds with strategic growth initiatives.
A major 2026 guidance increase could not satisfy investors expecting a faster earnings recovery next year.
CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and th
Moby summary of CVS Health Corporation's Q2 2026 earnings call
UnitedHealth's revenue held up; the operating margin on it did not, and closing that gap is the whole upside case.
July Private Payrolls Well Below Expectations .
After the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market.
CVS Health Corp (NYSE:CVS) reported second-quarter revenue and profit that beat Wall Street estimates on Wednesday, and raised its full-year adjusted earnings guidance, though cautious guidance pressured shares. Revenue rose 7.3% year-over-year to $106.1 billion, above analyst estimates of...
Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
CVS Health saw its shares dip about 6% even though it handily beat Wall Street’s expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company’s unusually early commentary about 2027.
(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.
CVS Health (NYSE:CVS) shares climbed around 5% in pre-market trading on Wednesday after the healthcare company reported second-quarter earnings that comfortably exceeded Wall Street expectations and increased its full-year profit forecast. The company posted earnings of $2.
CVS Health (CVS) delivered earnings and revenue surprises of +37.97% and +5.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share
Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.
Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 7.3% year on year to $106.1 billion. Its non-GAAP profit of $2.58 per share was 39.4% above analysts’ consensus estimates.
CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-quarter profit.
FEATURE Stock futures were rising on Wednesday, putting both the and the on track to notch record highs. SpaceX slumped 11% in premarket trading after the rockets, telecom, and AI company beat analysts’ second-quarter earnings target but reported higher capital expenditure than Wall Street was expecting.
Today Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.
CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
